STOCK TITAN

Coherus BioSciences, Inc. - CHRS STOCK NEWS

Welcome to our dedicated page for Coherus BioSciences news (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus BioSciences stock.

Coherus BioSciences, Inc. (NASDAQ: CHRS) is a leading commercial-stage biopharmaceutical company dedicated to improving patient access to high-quality, life-changing biologic medicines. Established in 2010 and headquartered in the San Francisco Bay Area, Coherus specializes in developing biosimilars and innovative immuno-oncology therapies to treat various chronic and life-threatening diseases.

Coherus' core business revolves around providing biosimilar therapeutics that are designed to replace existing branded biologics, thereby reducing healthcare costs. The company's biosimilar portfolio includes FDA-approved products like UDENYCA® (a biosimilar to Neulasta®) and YUSIMRY® (a biosimilar to Humira®), which is set to launch in the US in 2023. These products help manage conditions such as cancer and autoimmune diseases, expanding patient access to essential treatments.

Recently, Coherus completed the divestiture of its ophthalmology franchise, CIMERLI®, to Sandoz, Inc. for $170 million. This move allows Coherus to focus more intently on its immuno-oncology pipeline, which includes the promotion of LOQTORZI™ (toripalimab-tpzi), a next-generation PD-1 inhibitor approved for nasopharyngeal carcinoma. The company's strategy includes advancing its novel immuno-oncology candidates like CHS-114 and CHS-1000, which are in various stages of clinical development targeting solid tumors.

Financially, Coherus is leveraging the revenue from its biosimilar products to fund its immuno-oncology research and development. The company collaborates with global pharmaceutical partners across Europe, Asia, and Latin America, enhancing its market presence and resource capabilities.

Key updates include the successful preclinical data presentation for CHS-1000 at the 2024 AACR Annual Meeting, showcasing its potential to reverse immunosuppression in the tumor microenvironment. Moreover, the Cancer Research Institute (CRI) has selected LOQTORZI for combination studies to explore its efficacy in drug-resistant cancers, further solidifying Coherus' commitment to pioneering cancer therapy advancements.

Led by a team of seasoned industry veterans, Coherus BioSciences aims to become a global leader in the biosimilar and immuno-oncology markets, continually striving to develop therapies that improve patient outcomes and broaden access to high-quality medical treatments.

Rhea-AI Summary
Coherus BioSciences, Inc. (CHRS) reports strong financial results for Q4 2023 and FY 2023, with net revenue of $91.5 million and $257.2 million, respectively. Key highlights include UDENYCA® net sales of $36.2 million and CIMERLI® net sales of $52.4 million in Q4. The company successfully launched LOQTORZI™ and UDENYCA ONBODY™ in Q1 2024. However, a 30% workforce reduction for 2024 was initiated on March 7, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.65%
Tags
-
Rhea-AI Summary
Coherus BioSciences, Inc. announces the release of its fourth quarter and full year 2023 financial results on March 13, 2024. The management team will host a conference call and webcast to discuss the results and provide a business update. Investors can access the webcast and related materials on the Coherus website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences earnings
-
Rhea-AI Summary
Coherus BioSciences, Inc. (NASDAQ: CHRS) completes the divestiture of its CIMERLI ophthalmology franchise through the sale of Coherus Ophthalmology LLC to Sandoz, Inc. for $170 million in upfront cash. The transaction strengthens Coherus' capital structure and strategic focus in oncology, allowing the company to advance its immuno-oncology pipeline and launch LOQTORZI in nasopharyngeal carcinoma and UDENYCA ONBODY.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
none
Rhea-AI Summary
Coherus BioSciences, Inc. granted options to purchase 170,000 shares of common stock to newly hired employees. The options have an exercise price of $2.59 per share, based on the closing trading price on the grant date. The grants were made under the 2016 Employment Commencement Incentive Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
none
-
Rhea-AI Summary
Coherus BioSciences, Inc. launches UDENYCA ONBODY, an innovative on-body injector for pegfilgrastim-cbqv, with a five-minute delivery time and a retractable needle mechanism for cancer patients. Positive feedback from providers and patients indicates growing demand for UDENYCA, offering a convenient and safe treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
none
-
Rhea-AI Summary
Coherus BioSciences, Inc. has revised its loan agreement with Pharmakon Advisors, LP, reducing the principal balance to $75 million upon a projected paydown of $175 million in Q2 2024. The revenue covenant has also been reduced to $125 million, and the term loan annual interest expense is expected to be reduced by approximately 70%. This agreement follows the divestiture of the ophthalmology franchise to Sandoz, and the company aims to lower its projected annual interest payments significantly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
none
Rhea-AI Summary
Coherus BioSciences, Inc. (NASDAQ: CHRS) has announced the divestiture of its CIMERLI ophthalmology franchise to Sandoz for $170 million in upfront, all-cash consideration. The transaction aims to allow Coherus to focus on its core therapeutic area, oncology, by reducing debt, interest costs, and overhead costs. The company's oncology assets include the UDENYCA franchise, LOQTORZI, and an immuno-oncology pipeline of next-generation tumor microenvironment oncology drug candidates. The closing is anticipated in the first half of 2024, subject to certain closing conditions and approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
none
-
Rhea-AI Summary
Coherus BioSciences, Inc. presents promising data from the lead-in portion of the Phase 2 clinical trial evaluating casdozokitug in combination with atezolizumab and bevacizumab for the treatment of liver cancer. The data demonstrates a 38% objective response rate, including three complete responses, and supports continued evaluation of casdozokitug with VEGF and PD-(L)1 blockade in HCC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
-
Rhea-AI Summary
INOVIO (INO) and Coherus BioSciences (CHRS) to evaluate combination therapy in Phase 3 trial for patients with locoregionally advanced, high-risk, HPV16/18-positive head and neck cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
none
Rhea-AI Summary
Coherus BioSciences, Inc. (Nasdaq: CHRS) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
conferences

FAQ

What is the current stock price of Coherus BioSciences (CHRS)?

The current stock price of Coherus BioSciences (CHRS) is $1.24 as of January 24, 2025.

What is the market cap of Coherus BioSciences (CHRS)?

The market cap of Coherus BioSciences (CHRS) is approximately 153.2M.

What does Coherus BioSciences specialize in?

Coherus BioSciences specializes in developing high-quality biosimilar therapeutics and innovative immuno-oncology therapies to treat chronic and life-threatening diseases.

Where is Coherus BioSciences headquartered?

Coherus BioSciences is headquartered in the San Francisco Bay Area.

What are some of Coherus' FDA-approved products?

Coherus markets UDENYCA® (a biosimilar to Neulasta®) and YUSIMRY® (a biosimilar to Humira®), along with LOQTORZI™ (toripalimab-tpzi), a PD-1 inhibitor.

What recent transactions has Coherus BioSciences completed?

Coherus recently sold its CIMERLI® ophthalmology franchise to Sandoz, Inc. for $170 million.

How does Coherus BioSciences fund its immuno-oncology research?

Coherus leverages revenue generated from its diversified portfolio of FDA-approved biosimilars to fund its immuno-oncology research.

What is the significance of Coherus' partnership with the Cancer Research Institute?

The Cancer Research Institute has selected LOQTORZI for studies on drug-resistant cancers, highlighting the potential of Coherus' immuno-oncology treatments to advance patient care.

Which markets do Coherus' partnerships cover?

Coherus has commercialization partnerships with global pharmaceutical companies in Europe, Asia, and Latin America.

What recent achievements has Coherus made in its clinical pipeline?

Coherus presented promising preclinical data for CHS-1000 at the 2024 AACR Annual Meeting, demonstrating its potential to reverse tumor immunosuppression.

Who are the key figures in Coherus BioSciences' leadership?

Coherus is led by a team of industry veterans with decades of experience in pioneering biologics companies, including Chairman and CEO Denny Lanfear.

What is the focus of Coherus' CHS-114 clinical trials?

CHS-114, an anti-CCR8 antibody, is being evaluated in Phase 1 trials for its ability to selectively deplete tumor-resident regulatory T cells, enhancing anti-tumor immune response.
Coherus BioSciences, Inc.

Nasdaq:CHRS

CHRS Rankings

CHRS Stock Data

153.16M
110.62M
1.38%
70.28%
26.97%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
REDWOOD CITY